NuCana to present abstract on NUC-7738 and PD-1 inhibition synergy at ESMO Congress.

NuCana plc will present a poster at the upcoming ESMO Congress 2025 in Berlin, Germany. The poster, titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer," will be presented on Sunday, October 19, 2025. The abstract will be published online via the ESMO website on October 13, 2025.

NuCana plc, a clinical-stage biopharmaceutical company, will present data at the upcoming European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The presentation, titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer," will take place on Sunday, October 19, 2025. The abstract will be published online via the ESMO website on October 13, 2025 [1].

NuCana's presentation will focus on the synergy between its novel anti-cancer agent, NUC-7738, and PD-1 inhibitors in the treatment of renal cell cancer. NUC-7738 is a Phase 2 part of a Phase 1/2 study evaluating it as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. The study aims to demonstrate the potential of NUC-7738 in enhancing the efficacy of PD-1 inhibitors [1].

The company is also conducting a Phase 1b/2 modular study (NuTide:303) evaluating NUC-3373, a new chemical entity derived from 5-fluorouracil, in combination with pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer [1].

The presentation at ESMO Congress 2025 is a significant milestone for NuCana, providing an opportunity to showcase its innovative approach to cancer treatment. The company's proprietary technology, ProTide, transforms conventional chemotherapy agents into more effective and safer medicines by generating higher concentrations of anti-cancer metabolites in cancer cells [1].

For more information, please contact NuCana plc or ICR Healthcare.

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143493/0/en/NuCana-to-Present-Data-on-NUC-7738-s-Synergy-with-PD-1-Inhibitors-at-the-ESMO-Congress-2025.html